CoChat

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies.

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Blood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for disease identification across the AD continuum and the link to pathology is limited. This is partly due to heterogeneity in analytical methods. In this study, we employed an immunoprecipitation mass spectrometry method to simultaneously quantify six phosphorylated (p-tau181, p-tau199, p-tau202, p-tau205, p-tau217 and p-tau231) and two non-phosphorylated plasma tau peptides in a total of 214 participants from the Paris Lariboisière and Translational Biomarkers of Aging and Dementia cohorts. Our results indicate that p-tau217, p-tau231 and p-tau205 are the plasma tau forms that best reflect AD-related brain changes, although with distinct emergences along the disease course and correlations with AD features—amyloid and tau. These findings support the differential association of blood p-tau variants with AD pathology, and our method offers a potential tool for disease staging in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43587-023-00405-1

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Plasma tau species levels across clinical groups in cohort 2. Box plots of the z-scores in plasma p-tau181, tau212–221, p-tau217, tau195–209, p-tau199, p-tau202, p-tau205 and p-tau231 levels quantified by our MS method (n = 51). Participants were classified according to cognitive status: CU and CI and amyloid PET uptake positivity (centiloid > 24). To facilitate comparison among peptides, z-scores are provided; for absolute concentrations, see Supplementary Fig.3. CU− was used as the reference group. The box plots depict the median (horizontal bar) and 25th to 75th percentiles (hinges), and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided), and Tukey contrasts were used to account for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Exact significant P values: p-tau181 PCU− vs CI+ = 0.0352; p-tau205 PCU− vs CI+ < 0.001; p-tau217 PCU− vs CI+ < 0.001, PCU+ vs CI+ = 0.0148, PCI+ vs CI− = 0.0026; and p-tau231 PCU− vs CI+ = 0.0015.
Fig. 1 Plasma tau species levels across clinical groups in cohort 2. Box plots of the z-scores in plasma p-tau181, tau212–221, p-tau217, tau195–209, p-tau199, p-tau202, p-tau205 and p-tau231 levels quantified by our MS method (n = 51). Participants were classified according to cognitive status: CU and CI and amyloid PET uptake positivity (centiloid > 24). To facilitate comparison among peptides, z-scores are provided; for absolute concentrations, see Supplementary Fig.3. CU− was used as the reference group. The box plots depict the median (horizontal bar) and 25th to 75th percentiles (hinges), and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided), and Tukey contrasts were used to account for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Exact significant P values: p-tau181 PCU− vs CI+ = 0.0352; p-tau205 PCU− vs CI+ < 0.001; p-tau217 PCU− vs CI+ < 0.001, PCU+ vs CI+ = 0.0148, PCI+ vs CI− = 0.0026; and p-tau231 PCU− vs CI+ = 0.0015.CC BY · PubMed Central
Fig. 2 Association of plasma p-tau181, p-tau205, p-tau217 and p-tau231 with amyloid PET. a, Box plots of the z-scores in the levels of plasma p-tau181, p-tau205, p-tau217 and p-tau231 quantified by MS in participants classified in quartiles according to their amyloid PET uptake (Q1 = (−Inf, 1.29); Q2 = (1.29, 1.7); Q3 = (1.7, 2.45); Q4 = (2.45, Inf)) (n = 51). The reference group was Q1. To facilitate comparison among peptides, z-scores are provided; for absolute concentrations, see Supplementary Fig. 4. The box plots depict the median (horizontal bar) and 25th to 75th percentiles (hinges), and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using age-adjusted and sex-adjusted ANOVA (two-sided), and Tukey contrasts were used to account for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Exact significant P values: p-tau181 PQ1 vs Q4 = 0.0118; p-tau205 PQ1 vs Q4 < 0.001, PQ2 vs Q4 < 0.001, PQ3 vs Q4 = 0.0015; p-tau217 PQ1 vs Q4 < 0.001, PQ2 vs Q4 < 0.001, PQ3 vs Q4 < 0.001; p-tau231 PQ1 vs Q4 < 0.001, PQ2 vs Q4 = 0.0029, PQ3 vs Q4 = 0.0095. b, LOESS plots showing the smoothed relationship between biomarker levels and accumulation of amyloid pathology. Biomarker levels are presented as z-scores, using the average biomarker concentrations of the CU− group as reference. Amyloid pathology is indexed here by global amyloid PET SUVR, which was converted to the centiloid scale for comparison purposes. Horizontal dashed line indicates two z-scores, a likely indication of biomarker abnormality. Vertical dashed line indicates centiloid 24, the cutoff of amyloid positivity reported for TRIAD cohort. c, Voxel-wise associations of p-tau181, p-tau205, p-tau217 and p-tau231 with amyloid PET uptake. Unadjusted parametrical t-statistical maps depict the results of the association between plasma biomarkers and amyloid PET at the voxel level. Voxels with t > 3 have a significant association between the variables evaluated (maps adjusted for multiple comparisons are presented in Extended Data Fig. 5).
Fig. 2 Association of plasma p-tau181, p-tau205, p-tau217 and p-tau231 with amyloid PET. a, Box plots of the z-scores in the levels of plasma p-tau181, p-tau205, p-tau217 and p-tau231 quantified by MS in participants classified in quartiles according to their amyloid PET uptake (Q1 = (−Inf, 1.29); Q2 = (1.29, 1.7); Q3 = (1.7, 2.45); Q4 = (2.45, Inf)) (n = 51). The reference group was Q1. To facilitate comparison among peptides, z-scores are provided; for absolute concentrations, see Supplementary Fig. 4. The box plots depict the median (horizontal bar) and 25th to 75th percentiles (hinges), and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using age-adjusted and sex-adjusted ANOVA (two-sided), and Tukey contrasts were used to account for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Exact significant P values: p-tau181 PQ1 vs Q4 = 0.0118; p-tau205 PQ1 vs Q4 < 0.001, PQ2 vs Q4 < 0.001, PQ3 vs Q4 = 0.0015; p-tau217 PQ1 vs Q4 < 0.001, PQ2 vs Q4 < 0.001, PQ3 vs Q4 < 0.001; p-tau231 PQ1 vs Q4 < 0.001, PQ2 vs Q4 = 0.0029, PQ3 vs Q4 = 0.0095. b, LOESS plots showing the smoothed relationship between biomarker levels and accumulation of amyloid pathology. Biomarker levels are presented as z-scores, using the average biomarker concentrations of the CU− group as reference. Amyloid pathology is indexed here by global amyloid PET SUVR, which was converted to the centiloid scale for comparison purposes. Horizontal dashed line indicates two z-scores, a likely indication of biomarker abnormality. Vertical dashed line indicates centiloid 24, the cutoff of amyloid positivity reported for TRIAD cohort. c, Voxel-wise associations of p-tau181, p-tau205, p-tau217 and p-tau231 with amyloid PET uptake. Unadjusted parametrical t-statistical maps depict the results of the association between plasma biomarkers and amyloid PET at the voxel level. Voxels with t > 3 have a significant association between the variables evaluated (maps adjusted for multiple comparisons are presented in Extended Data Fig. 5).CC BY · PubMed Central
Fig. 3 Association of plasma p-tau181, p-tau205, p-tau217 and p-tau231 with tau PET. a, Box plots of the z-scores in the levels of plasma p-tau181, p-tau205, p-tau217 and p-tau231 quantified by MS in participants according to regional spreading of tau classified by Braak stages (n = 51). The reference group was Braak 0. To facilitate comparison among peptides, z-scores are provided; for absolute concentrations, see Supplementary Fig. 6. The box plots depict the median (horizontal bar) and 25th to 75th percentiles (hinges), and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using age-adjusted and sex-adjusted ANOVA (two-sided), and Tukey contrasts were used to account for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Exact significant P values: p-tau205 P0 vs V–VI < 0.001, PI–II vs V–VI < 0.001, PIII–IV vs V–VI = 0.0119; p-tau217 P0 vs V–VI < 0.001, P0 vs III–IV = 0.0082, PI–II vs V–VI < 0.001, PIII–IV vs V–VI = 0.0468; p-tau231 P0 vs V–VI < 0.001, P0 vs III–IV = 0.050. b, LOESS plots show the smoothed relationship between biomarker levels and Braak stages. Biomarker levels are presented as z-scores, using the average biomarker concentrations of the CU− group as reference. Horizontal dashed line indicates two z-scores, a likely indication of biomarker abnormality. c, Voxel-wise associations of p-tau181, p-tau205, p-tau217 and p-tau231 with tau PET uptake. Unadjusted parametrical t-statistical maps depict the results of the association between plasma biomarkers and tau PET at the voxel level. Voxels with t > 3 have a significant association between the variables evaluated (maps adjusted for multiple comparisons are presented in Extended Data Fig. 7).
Fig. 3 Association of plasma p-tau181, p-tau205, p-tau217 and p-tau231 with tau PET. a, Box plots of the z-scores in the levels of plasma p-tau181, p-tau205, p-tau217 and p-tau231 quantified by MS in participants according to regional spreading of tau classified by Braak stages (n = 51). The reference group was Braak 0. To facilitate comparison among peptides, z-scores are provided; for absolute concentrations, see Supplementary Fig. 6. The box plots depict the median (horizontal bar) and 25th to 75th percentiles (hinges), and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using age-adjusted and sex-adjusted ANOVA (two-sided), and Tukey contrasts were used to account for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001). Exact significant P values: p-tau205 P0 vs V–VI < 0.001, PI–II vs V–VI < 0.001, PIII–IV vs V–VI = 0.0119; p-tau217 P0 vs V–VI < 0.001, P0 vs III–IV = 0.0082, PI–II vs V–VI < 0.001, PIII–IV vs V–VI = 0.0468; p-tau231 P0 vs V–VI < 0.001, P0 vs III–IV = 0.050. b, LOESS plots show the smoothed relationship between biomarker levels and Braak stages. Biomarker levels are presented as z-scores, using the average biomarker concentrations of the CU− group as reference. Horizontal dashed line indicates two z-scores, a likely indication of biomarker abnormality. c, Voxel-wise associations of p-tau181, p-tau205, p-tau217 and p-tau231 with tau PET uptake. Unadjusted parametrical t-statistical maps depict the results of the association between plasma biomarkers and tau PET at the voxel level. Voxels with t > 3 have a significant association between the variables evaluated (maps adjusted for multiple comparisons are presented in Extended Data Fig. 7).CC BY · PubMed Central
Fig. 4 Amyloid and tau pathologies regression models for plasma p-tau181, p-tau205, p-tau217 and p-tau231 quantified by targeted MS. R2 and AIC are indicated for the different regression models, using only amyloid PET signal (A: indexed by global amyloid PET SUVR), only tau PET signal (T: indexed by global tau PET SUVR) or both amyloid and tau (A+T). The panel shows adjusted R2 for age and sex (inside the bars), together with AIC (above the bars) for each model (n = 51).
Fig. 4 Amyloid and tau pathologies regression models for plasma p-tau181, p-tau205, p-tau217 and p-tau231 quantified by targeted MS. R2 and AIC are indicated for the different regression models, using only amyloid PET signal (A: indexed by global amyloid PET SUVR), only tau PET signal (T: indexed by global tau PET SUVR) or both amyloid and tau (A+T). The panel shows adjusted R2 for age and sex (inside the bars), together with AIC (above the bars) for each model (n = 51).CC BY · PubMed Central
Extended Data Fig. 1 Differences in tau detection in blood by Immunoassays and Immunoprecipitation Mass Spectrometry (IP-MS). (A) Tau is truncated by proteolysis during pathophysiological processing. N-terminal and mid-region tau soluble fragments are generated in the brain and leak into CSF and plasma. Endogenous fragments found in CSF and plasma have been shown to end, among others, at aa123, aa224 and mainly at aa25714,15. (B) This creates a pool of distinct fragments to be detected in biofluids. (C) Immunoassays can only capture fragments with the specific length enclosed in the sandwich by the two pair of antibodies. Our IP, by combining 3 antibodies against non-phosphorylated tau -Tau 12 (aa6-18), HT7 (aa159-163) and BT2 (aa194-195) - can capture fragments of different lengths. (D) Further, the captured tau fragments are digested into peptides that are targeted by MS.
Extended Data Fig. 1 Differences in tau detection in blood by Immunoassays and Immunoprecipitation Mass Spectrometry (IP-MS). (A) Tau is truncated by proteolysis during pathophysiological processing. N-terminal and mid-region tau soluble fragments are generated in the brain and leak into CSF and plasma. Endogenous fragments found in CSF and plasma have been shown to end, among others, at aa123, aa224 and mainly at aa25714,15. (B) This creates a pool of distinct fragments to be detected in biofluids. (C) Immunoassays can only capture fragments with the specific length enclosed in the sandwich by the two pair of antibodies. Our IP, by combining 3 antibodies against non-phosphorylated tau -Tau 12 (aa6-18), HT7 (aa159-163) and BT2 (aa194-195) - can capture fragments of different lengths. (D) Further, the captured tau fragments are digested into peptides that are targeted by MS.CC BY · PubMed Central
Extended Data Fig. 2 Plasma tau species levels across clinical groups in Cohort 1. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, p-tau205 and p-tau231 levels quantified by our MS method (n=157). Participants were classified according to cognitive status and CSF Aβ42/40 ratio: CU (Cognitively unimpaired), MCI due to AD (Aβ positive Mild Cognitively Impaired), AD dementia, MCI not due to AD (Aβ negative Mild Cognitively Impaired) and other dementia (Aβ negative). The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P <0.01, ***P <0.001). Exact significant p-values: P-tau181 PCU vs MCI-AD<0.001, PCU vs AD<0.001, PMCI-AD vs MCI-nonAD=0.0023, PMCI-AD vs Other dementia=0.025, PAD vs MCI-nonAD<0.001, PAD vs Other dementia=0.0113; P-tau217 PCU vs AD<0.001, PAD vs MCI-nonAD<0.001, PAD vs Other dementia<0.001; P-tau199 PMCI-AD vs MCI-nonAD=0.0425; P-tau202 PMCI-AD vs MCI-nonAD=0.00164, PMCI-AD vs Other dementia=0.0063; P-tau231 PCU vs MCI-AD=0.0156, PCU vs AD <0.001, PMCI-AD vs MCI-nonAD=0.0185, PAD vs MCI-nonAD<0.001, PAD vs Other dementia<0.001.
Extended Data Fig. 2 Plasma tau species levels across clinical groups in Cohort 1. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, p-tau205 and p-tau231 levels quantified by our MS method (n=157). Participants were classified according to cognitive status and CSF Aβ42/40 ratio: CU (Cognitively unimpaired), MCI due to AD (Aβ positive Mild Cognitively Impaired), AD dementia, MCI not due to AD (Aβ negative Mild Cognitively Impaired) and other dementia (Aβ negative). The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P <0.01, ***P <0.001). Exact significant p-values: P-tau181 PCU vs MCI-AD<0.001, PCU vs AD<0.001, PMCI-AD vs MCI-nonAD=0.0023, PMCI-AD vs Other dementia=0.025, PAD vs MCI-nonAD<0.001, PAD vs Other dementia=0.0113; P-tau217 PCU vs AD<0.001, PAD vs MCI-nonAD<0.001, PAD vs Other dementia<0.001; P-tau199 PMCI-AD vs MCI-nonAD=0.0425; P-tau202 PMCI-AD vs MCI-nonAD=0.00164, PMCI-AD vs Other dementia=0.0063; P-tau231 PCU vs MCI-AD=0.0156, PCU vs AD <0.001, PMCI-AD vs MCI-nonAD=0.0185, PAD vs MCI-nonAD<0.001, PAD vs Other dementia<0.001.CC BY · PubMed Central
Extended Data Fig. 3 Plasma tau species levels across clinical groups in Cohort 2. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, tau195-209 and p-tau231 levels quantified by our MS method (n=51). Participants were classified according to cognitive status and amyloid PET uptake positivity: CU (Cognitively unimpaired) and CI (Cognitively Impaired). The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P <0.01, ***P <0.001). Exact significant p-values: P-tau181 PCU- vs CI+ = 0.0352; P-tau205 PCU- vs CI+ <0.001; P-tau217 PCU- vs CI+ <0.001, PCU+ vs CI+ = 0.0148, PCI+ vs CI- = 0.0026; and P-tau231 PCU- vs CI+ = 0.0015.
Extended Data Fig. 3 Plasma tau species levels across clinical groups in Cohort 2. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, tau195-209 and p-tau231 levels quantified by our MS method (n=51). Participants were classified according to cognitive status and amyloid PET uptake positivity: CU (Cognitively unimpaired) and CI (Cognitively Impaired). The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P <0.01, ***P <0.001). Exact significant p-values: P-tau181 PCU- vs CI+ = 0.0352; P-tau205 PCU- vs CI+ <0.001; P-tau217 PCU- vs CI+ <0.001, PCU+ vs CI+ = 0.0148, PCI+ vs CI- = 0.0026; and P-tau231 PCU- vs CI+ = 0.0015.CC BY · PubMed Central
Extended Data Fig. 4 Plasma tau species across Amyloid PET quartiles in Cohort 2. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, tau195-209 and p-tau231 levels in relation to amyloid PET (n=51). Participants were grouped in quartiles according to their levels of amyloid PET uptake (Q1=(-Inf,1.29]; Q2=(1.29,1.7]; Q3=(1.7,2.45]; Q4=(2.45, Inf]). The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P<0.01, ***P<0.001). Exact significant p-values: P-tau181 PQ1 vs Q4 =0.0118; P-tau205 PQ1 vs Q4 <0.001, PQ2 vs Q4 <0.001, PQ3 vs Q4 = 0.0015; P-tau217 PQ1 vs Q4 <0.001, PQ2 vs Q4 <0.001, PQ3 vs Q4 <0.001; P-tau231 PQ1 vs Q4 <0.001, PQ2 vs Q4 = 0.0029, PQ3 vs Q4 = 0.0095.
Extended Data Fig. 4 Plasma tau species across Amyloid PET quartiles in Cohort 2. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, tau195-209 and p-tau231 levels in relation to amyloid PET (n=51). Participants were grouped in quartiles according to their levels of amyloid PET uptake (Q1=(-Inf,1.29]; Q2=(1.29,1.7]; Q3=(1.7,2.45]; Q4=(2.45, Inf]). The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P<0.01, ***P<0.001). Exact significant p-values: P-tau181 PQ1 vs Q4 =0.0118; P-tau205 PQ1 vs Q4 <0.001, PQ2 vs Q4 <0.001, PQ3 vs Q4 = 0.0015; P-tau217 PQ1 vs Q4 <0.001, PQ2 vs Q4 <0.001, PQ3 vs Q4 <0.001; P-tau231 PQ1 vs Q4 <0.001, PQ2 vs Q4 = 0.0029, PQ3 vs Q4 = 0.0095.CC BY · PubMed Central
Extended Data Fig. 5 Voxel-wise associations of p-tau205, p-tau217 and p-tau231 with Amyloid PET uptake. Adjusted for multiple comparisons maps depict the results of the association between plasma biomarkers and Amyloid PET at the voxel level (n=51). Voxels with T-value>3 have a significant association between the variables evaluated. P-tau181 is not included in the figure since it did not survive adjustment for multiple comparisons.
Extended Data Fig. 5 Voxel-wise associations of p-tau205, p-tau217 and p-tau231 with Amyloid PET uptake. Adjusted for multiple comparisons maps depict the results of the association between plasma biomarkers and Amyloid PET at the voxel level (n=51). Voxels with T-value>3 have a significant association between the variables evaluated. P-tau181 is not included in the figure since it did not survive adjustment for multiple comparisons.CC BY · PubMed Central
Extended Data Fig. 6 Plasma tau species across Braak stages in Cohort 2. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, tau195-209 and p-tau231 levels in relation to amyloid PET (n=51). Participants were grouped in quartiles according to regional spreading of tau classified by Braak stages. The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P<0.01, ***P<0.001). Exact significant p-values: P-tau205 P0vsV-VI <0.001, PI-II vs V-VI <0.001, PIII-IV vs V-VI = 0.0119; P-tau217 P0 vs V-VI <0.001, P0 vs III-IV = 0.0082, PI-II vs V-VI <0.001, PIII-IV vs V-VI = 0.0468; P-tau231 P0 vs V-VI <0.001, P 0 vs III-IV= 0.050.
Extended Data Fig. 6 Plasma tau species across Braak stages in Cohort 2. Box plots of plasma p-tau181, tau212-221, p-tau217, p-tau199, p-tau202, tau195-209 and p-tau231 levels in relation to amyloid PET (n=51). Participants were grouped in quartiles according to regional spreading of tau classified by Braak stages. The boxplots depict the median (horizontal bar), 25th to 75th percentiles (hinges) and whiskers indicate 10th and 90th percentiles. Statistical analysis across groups was performed using ANOVA (two-sided) and Tukey Contrasts were used to account for multiple comparisons (*P<0.05, **P<0.01, ***P<0.001). Exact significant p-values: P-tau205 P0vsV-VI <0.001, PI-II vs V-VI <0.001, PIII-IV vs V-VI = 0.0119; P-tau217 P0 vs V-VI <0.001, P0 vs III-IV = 0.0082, PI-II vs V-VI <0.001, PIII-IV vs V-VI = 0.0468; P-tau231 P0 vs V-VI <0.001, P 0 vs III-IV= 0.050.CC BY · PubMed Central
Extended Data Fig. 7 Voxel-wise associations of p-tau205, p-tau217 and p-tau231 with Tau PET uptake. Adjusted for multiple comparisons maps depict the results of the association between plasma biomarkers and Amyloid PET at the voxel level (n=51). Voxels with T-value>3 have a significant association between the variables evaluated. P-tau181 is not included in the figure since it did not survive adjustment for multiple comparisons.
Extended Data Fig. 7 Voxel-wise associations of p-tau205, p-tau217 and p-tau231 with Tau PET uptake. Adjusted for multiple comparisons maps depict the results of the association between plasma biomarkers and Amyloid PET at the voxel level (n=51). Voxels with T-value>3 have a significant association between the variables evaluated. P-tau181 is not included in the figure since it did not survive adjustment for multiple comparisons.CC BY · PubMed Central
Extended Data Fig. 8 Linearity and recovery tests for the plasma tau IP-MS method. Linearity: plasma samples of different volumes (250, 500, 750 and 1000µl) were prepared and analyzed with the method. Simple linear regressions were performed (R2) and are shown for each peptide. Recovery: total-tau protein concentration before and after immunoprecipitation (IP) performed for sample preparation before MS analysis (n=3). Data shown as mean ± SD.
Extended Data Fig. 8 Linearity and recovery tests for the plasma tau IP-MS method. Linearity: plasma samples of different volumes (250, 500, 750 and 1000µl) were prepared and analyzed with the method. Simple linear regressions were performed (R2) and are shown for each peptide. Recovery: total-tau protein concentration before and after immunoprecipitation (IP) performed for sample preparation before MS analysis (n=3). Data shown as mean ± SD.CC BY · PubMed Central
Extended Data Fig. 9 Correlation between IP-MS and Simoa quantification for p-tau181, p-tau217 and p-tau231 in the TRIAD cohort. Participants are color coded according to cognitive status: CU (Cognitively unimpaired) and CI (Cognitively Impaired), and amyloid PET uptake positivity (Centiloid>24): blue (CU-), orange (CU+), red (CI+) and dark grey (CI-). Spearman rho correlation were: Rp-tau181=0.83 (P<2.2x10-16), Rp-tau217=0.82 (P<2.2x10-16) and Rp-tau231=0.83 (P<2.2x10-16). P-values two-sided.
Extended Data Fig. 9 Correlation between IP-MS and Simoa quantification for p-tau181, p-tau217 and p-tau231 in the TRIAD cohort. Participants are color coded according to cognitive status: CU (Cognitively unimpaired) and CI (Cognitively Impaired), and amyloid PET uptake positivity (Centiloid>24): blue (CU-), orange (CU+), red (CI+) and dark grey (CI-). Spearman rho correlation were: Rp-tau181=0.83 (P<2.2x10-16), Rp-tau217=0.82 (P<2.2x10-16) and Rp-tau231=0.83 (P<2.2x10-16). P-values two-sided.CC BY · PubMed Central
Extended Data Fig. 10 Plasma tau peptides quantification in the Discovery Cohort. Plasma samples from 24 participants in the H70 Clinical Studies (12 AD and 12 controls (Ctrl)) were analyzed with the IP-LC/MS method. Samples were selected according to their corresponding CSF biomarker values: Aβ42/40 ratio < 0.062 and p-tau > 60 ng/L. Data shown as mean ± SD.
Extended Data Fig. 10 Plasma tau peptides quantification in the Discovery Cohort. Plasma samples from 24 participants in the H70 Clinical Studies (12 AD and 12 controls (Ctrl)) were analyzed with the IP-LC/MS method. Samples were selected according to their corresponding CSF biomarker values: Aβ42/40 ratio < 0.062 and p-tau > 60 ng/L. Data shown as mean ± SD.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 138

Metadata

Authors
Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., Rahmouni, N., Brinkmalm, G., Lussier, F. Z., Pascoal, T. A., Skoog, I., Kern, S., Zetterberg, H., Paquet, C., Gobom, J., Rosa-Neto, P., & Blennow, K.
Affiliations
  • University of Gothenburg (SE)
  • Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l’Île-de-Montréal (CA)
  • Inserm (FR)
  • King's College London (GB)
  • Universidade Federal do Rio Grande do Sul (BR)
  • University of Pittsburgh (US)
  • Sahlgrenska University Hospital (SE)
  • University of Wisconsin–Madison (US)
Corresponding author
Blennow, Kaj
Venue
Nature Aging
Published
2023-04-27
Volume
3
Issue
6
Pages
661-669
ISSN
2662-8465 (ISSN-L)
OpenAlex
W4367321693
Cited by
122
References
41
Citations by year
2026: 26 · 2025: 51 · 2024: 37 · 2023: 8
FWCI
21.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Aging (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
Funders
  • BrightFocus Foundation (A2022015F)
  • Familjen Erling-Perssons Stiftelse (FO2022-0270, ALFGBG-71320, ADSF-21-831377-C, #ADSF-21-831381-C, 860197, 101053962, #201809-2016862, ADSF-21-831376-C)
  • Gun och Bertil Stohnes Stiftelse
  • Stiftelsen för Gamla Tjänarinnor (2020-00959, FO2022‐0270, 860197)
  • Fondation Vaincre Alzheimer
  • European Commission (-71320, ADSF-21-831377-C, FO2022-0270, ADSF-21-831381-C, 201809-2016862, 101,053,962, HORIZON2020, ALFGBG-71320, 860197, ADSF-21-831376-C)
  • Hjärnfonden (#FO2022-0270, 860197)
  • Vetenskapsrådet (FO2022-0270, ADSF-21-831377-C, #101053962, 860197, ADSF-21-831376-C, ALFGBG‐71320, 201809-2016862, 02532, 2018-, #ADSF-21-831381-C, 2018-02532)
  • Göteborgs Universitet
  • Alzheimerfonden (AF‐968621)
  • Demensfonden
  • Olav Thon Stiftelsen
  • HORIZON EUROPE Framework Programme (101053962, 860197)
  • National Institute on Aging (R01AG068398)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
Keywords
phosphorylated tau, plasma tau, Alzheimer's disease, blood biomarkers, tau phosphorylation sites, p-tau217, p-tau231, amyloid, tau pathology, immunoprecipitation mass spectrometry, disease staging
MeSH terms
Alzheimer Disease, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Amyloidogenic Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. https://app.cochat.ai/papers/10.1038/s43587-023-00405-1
The paper
Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., Rahmouni, N., Brinkmalm, G., Lussier, F. Z., Pascoal, T. A., Skoog, I., Kern, S., Zetterberg, H., Paquet, C., Gobom, J., . . . Blennow, K. (2023). Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nature Aging. https://doi.org/10.1038/s43587-023-00405-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.